X

Trial Profile

A Phase 2 Study of Kevetrin (Thioureidobutyronitrile) in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Thioureidobutyronitrile (Primary)
Indications Ovarian cancer
Focus Adverse reactions; Pharmacodynamics
Sponsors Innovation Pharmaceuticals

Most Recent Events

08 Feb 2018 Status changed from recruiting to completed, according to an Innovation Pharmaceuticals media release.
27 Dec 2017 Preliminary data from the first patients in this trial presented in an Innovation Pharmaceuticals media release.
14 Sep 2017 According to an iPharma media release, the company expects initial primary results in 4th quarter 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com